BioCat and ALPCO Diagnostics Sign Exclusive Distribution Agreement
News Nov 20, 2012
BioCat has announced the signing of an exclusive distribution agreement with ALPCO Diagnostics.
Representatives of BioCat and ALPCO met in the course of the MEDICA 2012 in Düsseldorf, Germany, the world's largest medical trade fair, to sign the agreement.
ALPCO Diagnostics is renowned for their insulin ELISA kits and other market-leading metabolism assays.
The ALPCO assays cover all aspects of metabolism and associated diseases, for example assays for factors involved in diabetes and obesity or cardiovascular diseases.
Dr. Michael Ehret, CEO at BioCat comments: "Thanks to the outstanding quality of the ALPCO ELISA kits we were able to build a solid customer base in the past. The exclusive distribution agreement will bring this collaboration to a new level."
Karen Stein, Vice President of Sales and Marketing for ALPCO Diagnostics, stated: "We are very excited to have BioCat as our exclusive distributor in Germany. They are well known for their commitment to life science research and their excellent technical support, making them an ideal partner to represent ALPCO in Germany."
Chinese researchers have developed interfacially polymerized porous polymer particles for low- abundance glycopeptide separation. These polymer particles - with hydrophilic-hydrophobic heterostructured nanopores - can separate low-abundance glycopeptides from complex biological samples with high-abundance background molecules efficiently.